Lundbeck rises on strong sales and earnings growth

7 February 2023

Shares of Denmark’s Lundbeck (LUND: CO) were up more than 9% this morning, after the CNS specialist released its 2022 financial results, showing that growth of its strategic brands accelerated further with an increase of 31% (+20% in local currencies) in 2022, reaching 12.1 billion kroner ($1.76 billion), and representing 67% of overall revenue.

Lundbeck posted fourth-quarter sales up 15% to 4.68 million kroner, above the 4.56 million kroner forecast by analysts in a poll carried out by the company. Its earnings before interest, taxes, depreciation and amortization (EBITDA more than doubled to 910 million kroner, though fell short of the 940 million kroner forecast by analysts.

Total revenue increased by 12% (+7% in local currencies) to 18,246 million, with all markets contributing strongly, particularly the USA, where sales were up 22% reported to 9,102 million kroner (+7% in local currencies).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK